These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 2140205

  • 1. Effect of protein C and activated protein C on coagulation and fibrinolysis in normal human subjects.
    Okajima K, Koga S, Kaji M, Inoue M, Nakagaki T, Funatsu A, Okabe H, Takatsuki K, Aoki N.
    Thromb Haemost; 1990 Feb 19; 63(1):48-53. PubMed ID: 2140205
    [Abstract] [Full Text] [Related]

  • 2. Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers.
    Siegbahn A, Ruusuvaara L.
    Thromb Haemost; 1988 Dec 22; 60(3):361-4. PubMed ID: 3149043
    [Abstract] [Full Text] [Related]

  • 3. Comparative effects of the human protein C activator, Protac, on the activated partial thromboplastin clotting times of plasmas, with special reference to the dog.
    Johnstone IB, Martin CA.
    Can J Vet Res; 2000 Apr 22; 64(2):117-22. PubMed ID: 10805251
    [Abstract] [Full Text] [Related]

  • 4. The effects of supra-normal protein C levels on markers of coagulation, fibrinolysis and inflammation in a human model of endotoxemia.
    Spiel AO, Firbas C, Mayr FB, Leitner JM, Schmidt B, Knöbl P, Varadi K, Jilma B.
    Thromb Haemost; 2005 Dec 22; 94(6):1148-55. PubMed ID: 16411386
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A prothrombinase-based assay for detection of resistance to activated protein C.
    Nicolaes GA, Thomassen MC, van Oerle R, Hamulyak K, Hemker HC, Tans G, Rosing J.
    Thromb Haemost; 1996 Sep 22; 76(3):404-10. PubMed ID: 8883278
    [Abstract] [Full Text] [Related]

  • 7. Effects of activated protein C on coagulation and fibrinolysis in rabbits with endotoxin induced acute lung injury.
    He HY, Wang C, Pang BS.
    Chin Med J (Engl); 2008 Dec 20; 121(24):2561-5. PubMed ID: 19187596
    [Abstract] [Full Text] [Related]

  • 8. Activated human protein C prevents thrombin-induced thromboembolism in mice. Evidence that activated protein c reduces intravascular fibrin accumulation through the inhibition of additional thrombin generation.
    Gresele P, Momi S, Berrettini M, Nenci GG, Schwarz HP, Semeraro N, Colucci M.
    J Clin Invest; 1998 Feb 01; 101(3):667-76. PubMed ID: 9449701
    [Abstract] [Full Text] [Related]

  • 9. An antifibrinolytic effect associated with an anti-factor V antibody in a patient with severe thrombophilia.
    Colucci M, Simioni P, Piro D, Prandoni P, Pagnan A, Semeraro N.
    Haematologica; 2003 Dec 01; 88(12):1383-9. PubMed ID: 14687992
    [Abstract] [Full Text] [Related]

  • 10. Plasma levels and urinary excretion of fibrinolytic and protease inhibitory proteins in nephrotic syndrome.
    Vaziri ND, Gonzales EC, Shayestehfar B, Barton CH.
    J Lab Clin Med; 1994 Jul 01; 124(1):118-24. PubMed ID: 7518491
    [Abstract] [Full Text] [Related]

  • 11. Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity.
    Erem C.
    Clin Endocrinol (Oxf); 2006 Mar 01; 64(3):323-9. PubMed ID: 16487444
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Pharmacokinetics of human activated protein C. 1st communication: plasma concentration and excretion of a lyophilized purified human activated protein C after intravenous administration in the mouse and the rabbit.
    Ishii S, Mochizuki T, Nagao T, Sugiki S, Kudo S, Harakawa N, Taniguchi K, Igarashi Y, Kondo S, Kiyoki M.
    Arzneimittelforschung; 1995 May 01; 45(5):636-44. PubMed ID: 7612068
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Peritoneal lavage with activated protein C alters compartmentalized coagulation and fibrinolysis and improves survival in polymicrobial peritonitis.
    van Veen SQ, Levi M, van Vliet AK, Florquin S, van Gulik TM, Boermeester MA.
    Crit Care Med; 2006 Nov 01; 34(11):2799-805. PubMed ID: 17006359
    [Abstract] [Full Text] [Related]

  • 16. [Recombinant tissue-type plasminogen activator: pharmacokinetics and effect on the hemostasis system of the human].
    Seifried E, Böck F, Tanswell P, Rijken DC, Kluft C, Heimpel H.
    Klin Wochenschr; 1988 Nov 01; 66 Suppl 12():40-9. PubMed ID: 2450222
    [Abstract] [Full Text] [Related]

  • 17. [Inhibitory effect of activated protein C and heparin on arterial thrombosis].
    Araki H.
    Nihon Rinsho; 1992 Feb 01; 50(2):408-12. PubMed ID: 1613999
    [Abstract] [Full Text] [Related]

  • 18. [Role of protein C in endotoxin-induced release of plasminogen activator inhibitor from endothelial cell].
    Okajima K, Koga S, Nakagaki T, Okabe H, Funatsu A, Takatsuki K.
    Nihon Ketsueki Gakkai Zasshi; 1989 Nov 01; 52(7):1159-64. PubMed ID: 2618561
    [Abstract] [Full Text] [Related]

  • 19. Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis.
    Jankun J, Aleem AM, Selman SH, Skrzypczak-Jankun E, Lysiak-Szydlowska W, Grafos N, Fryer HJ, Greenfield RS.
    Int J Mol Med; 2007 Nov 01; 20(5):683-7. PubMed ID: 17912461
    [Abstract] [Full Text] [Related]

  • 20. Cutaneous and systemic effects of varying doses of brown recluse spider venom in a rabbit model.
    McGlasson DL, Harroff HH, Sutton J, Dick E, Elston DM.
    Clin Lab Sci; 2007 Nov 01; 20(2):99-105. PubMed ID: 17557708
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.